A biopsy-based genomic assay that would discriminate between aggressive prostate cancer and indolent disease to guide treatment decisions is under development.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.